Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis

Evgeny Izumchenko, David Sidransky

Research output: Contribution to journalComment/debate

Abstract

With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding of EGFR regulation by MIG6 and reveals that MIG6 antagonizes tumor formation in mutant EGFR-driven lung adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)472-474
Number of pages3
JournalCancer Discovery
Volume5
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Lung Neoplasms
Carcinogenesis
Clinical Trials
Lung
Neoplasms
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis. / Izumchenko, Evgeny; Sidransky, David.

In: Cancer Discovery, Vol. 5, No. 5, 01.05.2015, p. 472-474.

Research output: Contribution to journalComment/debate

@article{8c579f1c897b465ca3529bf4b97fb9bc,
title = "Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis",
abstract = "With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding of EGFR regulation by MIG6 and reveals that MIG6 antagonizes tumor formation in mutant EGFR-driven lung adenocarcinoma.",
author = "Evgeny Izumchenko and David Sidransky",
year = "2015",
month = "5",
day = "1",
doi = "10.1158/2159-8290.CD-15-0336",
language = "English (US)",
volume = "5",
pages = "472--474",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis

AU - Izumchenko, Evgeny

AU - Sidransky, David

PY - 2015/5/1

Y1 - 2015/5/1

N2 - With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding of EGFR regulation by MIG6 and reveals that MIG6 antagonizes tumor formation in mutant EGFR-driven lung adenocarcinoma.

AB - With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding of EGFR regulation by MIG6 and reveals that MIG6 antagonizes tumor formation in mutant EGFR-driven lung adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84975824121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975824121&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-0336

DO - 10.1158/2159-8290.CD-15-0336

M3 - Comment/debate

C2 - 25941338

AN - SCOPUS:84975824121

VL - 5

SP - 472

EP - 474

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 5

ER -